Last reviewed · How we verify

Qwo

DMR Research, PLLC · FDA-approved active Small molecule

Qwo is a mixture of collagenase clostridium histolyticum enzymes that enzymatically breaks down collagen in subcutaneous tissue to reduce the appearance of cellulite.

Qwo is a mixture of collagenase clostridium histolyticum enzymes that enzymatically breaks down collagen in subcutaneous tissue to reduce the appearance of cellulite. Used for Cellulite in women of reproductive age.

At a glance

Generic nameQwo
SponsorDMR Research, PLLC
Drug classCollagenase enzyme
TargetCollagen types I and III
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Qwo contains two purified collagenase enzymes derived from Clostridium histolyticum that directly cleave collagen types I and III in the dermal and subcutaneous layers. By degrading the structural collagen that contributes to the dimpled appearance of cellulite, the treatment reduces cellulite severity. The enzymes work locally at the injection site to remodel the fibrous septae responsible for the characteristic cellulite appearance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: